Built by leaders at the forefront of
 genetic medicine

Dr. Lee has been CEO of BreezeBio since he founded the company to build and commercialize an innovative solution to the problem of genetic medicine delivery. He developed the NanoGalaxy platform that demonstrated efficient delivery to specific target tissues and he is an inventor on a dozen patents. He has published several high-profile papers in Nature journals that demonstrate delivery of mRNA, protein therapeutics and CRISPR therapeutics. He was named as a Forbes 30 under 30 in 2017 and was named as a Siebel Scholar. He completed his Ph.D. at UC Berkeley and UCSF in the Department of Bioengineering where he focused on novel delivery systems for macromolecular therapeutics. He holds a BS from KAIST.

Dr. Mora leads R&D with a focus on developing clinical assets for immunology. He has over 25 years of experience across academia and the biotech/pharma industry, specializing in immunology and inflammatory diseases. Prior to BreezeBio, he was faculty at Harvard Medical School and a research lab head at Massachusetts General Hospital. He also served as Vice President of Immunoengineering at Moderna, where he provided scientific leadership, clinical development expertise and cross-functional team management and mentoring, while advancing innovative research strategies. His career also includes additional senior scientific and leadership roles, including Head of Immune Cell-Therapy Engineering and Senior Medical Director at Takeda as well as Associate Scientific Director of Inflammatory Bowel Disease/Immunology at Janssen. With more than 50 publications and over 14,000 citations, he has made extensive contributions to both industry and academia, bridging cutting-edge science with translational medicine. Dr. Mora obtained his MD at University of La Frontera, his PhD at the University of Chile and did his postdoctoral training at Harvard Medical School.

Mr. Kim leads business development and strategic planning at BreezeBio. He has over 20 years of biopharmaceutical experience in corporate and business development, strategy and finance. He has led high-value transactions across multiple therapeutic areas, including autoimmune and rare diseases, with a strong track record of leading global partnering deals and acquisitions. Prior to BreezeBio, he led business development as VP, Corporate Development at Mirum Pharmaceuticals and Aduro Biotech (acquired by Chinook/Novartis).  Previously, he held business development and finance roles at OncoMed Pharmaceuticals, Onyx Pharmaceuticals (acquired by Amgen) and Amgen.  He holds an MBA from the University of Michigan Business School and a BS from UC Berkeley.

Dr. Park co-founded BreezeBio and has been instrumental in building the company. He leads the company’s strategic financial direction and operational efficiency. His responsibilities extend across all administrative functions, including HR, facilities, IT, accounting, budgeting and investor relations. His deep involvement in financial planning, risk management and resource allocation helps ensure the company’s sustainability and growth. Additionally, Dr. Park’s technical expertise spans multiple components of BreezeBio’s technology: he has published multiple in vivo studies and he is a co-inventor of CRISPR-12a technology that was licensed to Editas. In the early days of the company, he led a research team to establish in vivo preclinical screening methods and the demonstration of efficient delivery to specific target tissues. Prior to BreezeBio, he completed his Ph.D. at UC Berkeley. He holds an MS and BS from Korea University.

Dr. Kim leads the South Korean team and is responsible for both strategy and R&D for multiple cutting-edge projects. Prior to BreezeBio, he worked at ToolGen, where he made significant contributions to the development of various genome editing technologies, including ZFN, TALEN and CRISPR and explored their applications using diverse delivery modalities for therapeutic genome editing programs. During his tenure at ToolGen as Research Director and Executive Director for R&D Strategy and Alliances, he also played a pivotal role in securing substantial funding, establishing R&D and BD departments and leading research programs that resulted in multiple licensing agreements. Throughout his career, Dr. Kim has authored numerous peer-reviewed research papers based on his work in genome editing and gene therapy, cementing his position as a leading expert in the field. He began his career in genome editing in 2007 as a postdoctoral researcher at Seoul National University after earning a Ph.D. in Molecular Medicine from the University of Texas Health Science Center at San Antonio. He holds an BE from Handong University.

Mr. Kang leads finance, accounting and investor relations. He has more than 25 years of experience spanning R&D and finance, with the majority of his career focused on corporate finance, M&A and strategic leadership as a CPA, equity analyst and start-up CFO across diverse industries including tech hardware, biopharmaceuticals and e-commerce platforms. Prior to joining BreezeBio, he served as CFO and Board member at Cellatoz Therapeutics, Kurly and BIOCND (acquired by PharmaResearch) where he led FP&A, corporate financing and IPO preparation as well as successfully executed M&A transactions with listed biotechs and global private equity. Earlier in his career, he worked as a tech analyst at Standard Chartered Securities. He holds a BS and MS in organic chemistry from Seoul National University. 

Dr. Sloan leads immunology and formulation teams and multiple external research collaborations. He has more than 15 years of experience in biotech and pharma leading the discovery and development of immune-based biologic therapeutics. Prior to BreezeBio, as a Senior Director at Vir Biotechnology and Agenovir, his teams advanced an mRNA and nanoparticle-based CRISPR therapeutic to Pre-IND. At Gilead Sciences, his HIV Cure team generated IND-enabling data for a combination antibody and immune modulator drug candidate that advanced into the clinic. At Cero, MedImmune and Immune Design, he led R&D efforts for CAR-T and viral vaccine programs. Dr. Sloan has 10 years of post-graduate research experience at UC San Diego and at the University of Washington, including as a Principal Investigator. His academic research focused on cancer biology and mechanisms of viral immune evasion. He holds a BA in immunology from UC Berkeley and an MD from the UC San Diego School of Medicine.

Dr. Bodovitz leads strategic pipeline planning for the entire portfolio of HNPs. Prior to BreezeBio, he was an Associate Director of Strategic Development and then Associate Director of Market Planning at Aduro Biotech. He was employee #13 and worked closely with the management team to build the company. Following a successful IPO, he joined the commercial team to assess market opportunities for a broad portfolio of antibodies, small molecules and cell-based therapies. Prior to Aduro, he was Principal at BioPerspectives, where he identified market opportunities for therapeutics, diagnostics and drug discovery technologies. He was featured as a Proteomics Pioneer in ProteoMonitor and quoted in articles in The Economist, Nature Biotechnology, Science and Genetic Engineering & Biotechnology News. He obtained his Ph.D. in Neuroscience from Northwestern University and his BA in biochemistry and cell biology from the University of California at San Diego.

Dr. Lee has been CEO of BreezeBio since he founded the company to build and commercialize an innovative solution to the problem of genetic medicine delivery. He developed the NanoGalaxy platform that demonstrated efficient delivery to specific target tissues and he is an inventor on a dozen patents. He has published several high-profile papers in Nature journals that demonstrate delivery of mRNA, protein therapeutics and CRISPR therapeutics. He was named as a Forbes 30 under 30 in 2017 and was named as a Siebel Scholar. He completed his Ph.D. at UC Berkeley and UCSF in the Department of Bioengineering where he focused on novel delivery systems for macromolecular therapeutics. He holds a BS from KAIST.

Dr. Park co-founded BreezeBio and has been instrumental in building the company. He leads the company’s strategic financial direction and operational efficiency. His responsibilities extend across all administrative functions, including HR, facilities, IT, accounting, budgeting and investor relations. His deep involvement in financial planning, risk management and resource allocation helps ensure the company’s sustainability and growth. Additionally, Dr. Park’s technical expertise spans multiple components of BreezeBio’s technology: he has published multiple in vivo studies and he is a co-inventor of CRISPR-12a technology that was licensed to Editas. In the early days of the company, he led a research team to establish in vivo preclinical screening methods and the demonstration of efficient delivery to specific target tissues. Prior to BreezeBio, he completed his Ph.D. at UC Berkeley. He holds an MS and BS from Korea University.